{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:40:27Z","timestamp":1759624827798,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.eururo.2023.12.019","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T20:08:16Z","timestamp":1708200496000},"page":"500-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial"],"prefix":"10.1016","volume":"85","author":[{"given":"Marco","family":"Moschini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.12.019_b0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.12.019_b0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.12.019_b0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.12.019_b0020","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2023.12.019_b0025","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.12.019_b0030","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.urology.2010.01.087","article-title":"Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions","volume":"76","author":"Hedgepeth","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.12.019_b0035","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.12.019_b0040","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2023.12.019_b0045","doi-asserted-by":"crossref","unstructured":"Necchi A, Basile G, Gibb EA, et al. VI\u2010RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle\u2010invasive bladder cancer. BJU Int. In press. https:\/\/doi.org\/10.1111\/bju.16191","DOI":"10.1111\/bju.16191"},{"key":"10.1016\/j.eururo.2023.12.019_b0050","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.12.019_b0055","doi-asserted-by":"crossref","unstructured":"Crupi E, de Padua TC, Marandino L, et al. Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: a systematic review. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2023.05.012","DOI":"10.1016\/j.euo.2023.05.012"},{"key":"10.1016\/j.eururo.2023.12.019_b0060","doi-asserted-by":"crossref","unstructured":"Kamat AM, Apolo AB, Babjuk M, et al. Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. In press. https:\/\/doi.org\/10.1200\/JCO.23.00307","DOI":"10.1200\/JCO.23.00307"},{"key":"10.1016\/j.eururo.2023.12.019_b0065","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1200\/JCO.23.00280","article-title":"Evaluating trials of adjuvant therapy: is there benefit for people with resected renal cancer?","volume":"41","author":"Tannock","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382400068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382400068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:14:49Z","timestamp":1759583689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382400068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S030228382400068X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.12.019","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}